ASCO 2026 | The importance of alloSCT in improving outcomes for patients with BPDCN

So very important in the journey of BPDCN is highlighting how deadly this disease has been for our patients. It’s actually very sobering to think about the historical expectation for median overall survival in BPDCN has only been 8 to 12 months. Now that’s prior to the CD123 targeted era, but even with the CD123 targeted drugs, we’ve made a modest improvement in overall survival for sure, but it’s modest with single agent monotherapy alone. So we’re asking the question how to add to that. And one clear way has been that of stem cell transplant, primarily allogeneic stem cell transplant. The key here is that no matter what you do to treat the BPDCN upfront, whether it’s HMA, VEN, cytotoxic chemo, such as hyper-CVAD, CD123, our goal still remains in 2026 for allogeneic transplant in CR1. And that’s because we’ve seen improved outcomes in terms of median overall survival. The caveat has always been with allogeneic transplant that A, you need to be usually younger and B, fitter, although we are pushing the envelope now in terms of transplanting patients who are older and, of course, different types of donors. And so the key concept that our group and others have published is that you are able to, after CD123 targeted therapy, to move to an allogeneic transplant, and I will say in some exceptional cases, autotransplant as well, we recommend doing it upfront as a consolidation in the first remission to improve outcomes for patients.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.